Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Recruiting 6Active not recruiting 5Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 303Carcinoma, Non-Small-Cell Lung 240Prostatic Neoplasms 196Neoplasms 190Lung Neoplasms 149Multiple Myeloma 141Neoplasm Metastasis 110Colorectal Neoplasms 104Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 82Pancreatic Neoplasms 76Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 69Carcinoma, Renal Cell 67Squamous Cell Carcinoma of Head and Neck 62Lymphoma, Non-Hodgkin 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 60Urinary Bladder Neoplasms 58Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Recurrence 54Glioblastoma 53Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Endometrial Neoplasms 50Stomach Neoplasms 46Sarcoma 46

Interventions

pertuzumab 2tucatinib 1atezolizumab 1Trastuzumab 1Paclitaxel 1Docetaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Breast Cancer × 90 days × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Active not recruiting
83 enrolled
Breast

HER2-positive Breast Cancer

NCT06968585 2026-05-08

A166

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
365 enrolled
Breast

HER2-positive Breast Cancer

NCT05705401 2026-04-27

HERO

NRG Oncology

Phase 3 Active not recruiting
1,300 enrolled
Breast

HER2-positive Breast Cancer

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Seagen Inc.

Phase 3 Active not recruiting
466 enrolled 17 charts
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡